Helping patients by changing my habits: Observations from the DISCHARGE Trial

A habit cannot be tossed out the window; it must be coaxed down the stairs a step at a time.

– Mark Twain

Each time we meet with a patient to discuss known or suspected heart disease, a conversation about their daily habits ensues. Do they walk regularly? What does their usual diet include? Smoking, stress, and sleep are all topics of interest as we work to better understand how their choices might be impacting their heart health.

But rarely are the tables turned in such a way that the patient begins asking how the clinician’s regular choices might impact the patient’s heart health. We might discuss the pros and cons of a treatment option, but do we consider how our “clinical habits” might actually be increasing a patient’s risk?

The DISCHARGE Trial, published in the New England Journal of Medicine, forcefully makes the case that our “clinical habits” do indeed impact a patient’s overall risk, meaning that we need to carefully assess our own habits as we assess those of our patients.

The clinical team leading the DISCHARGE Trial randomized over 3,500 patients with stable chest pain and intermediate-to-high probability of obstructive coronary artery disease (CAD) who had been referred to the cath lab for invasive coronary angiography (ICA). Like many of the most perplexing cardiology cases, the majority of these patients had continuing symptoms that were unimproved by medication or had stress tests that were nondiagnostic.

At this point, with patients on their way to the cath lab, each was randomized between either usual care (continue on to ICA) or a coronary CT angiogram (CTA).

3.5 years of subsequent follow-up revealed several important findings about those patients sent for coronary CTA in lieu of the cath lab:

These data invite all cardiologists to ask “Do my habits put patients at risk?” Do our common clinical choices, which we have learned to make through hard-earned experiences in training and clinical practice, potentially expose our patients to risks that could be reduced if we were to step back and reassess why we do what we do?

For example, a wonderfully thoughtful cardiologist recently explained to me that while he has shifted his patients toward a CTA+FFRCT pathway to better inform his clinical decision making, some of his partners have not adopted a CTA-driven pathway. These partners consistently refer to ICA those patients who are unresponsive to medical therapy or have nondiagnostic or indeterminate stress tests.

There is no question that these cardiologists are working to care responsibly for their patients by using a tool that has been a standard for years. However, there is a question as to whether the use of diagnostic ICA for these patients in whom CAD has not been anatomically identified by CTA is worth the nearly 4x increase in procedural complications and the startlingly high rates of finding no obstructive CAD.

On the heels of the new ACC/AHA Chest Pain Guidelines, many clinicians are reconsidering how they evaluate and diagnose chest pain. As we assess our clinical habits, we create an opportunity to change patterns, one patient at a time. The DISCHARGE Trial clearly demonstrates that a small adjustment, in this case the expanded use of coronary CTA to better identify CAD, delivers significant, lasting benefits to many of our patients.

— A perspective from HeartFlow Chief Medical Officer, Campbell Rogers, MD
Bio | LinkedIn

Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます!


HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。


さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please apply for research grants through our online submission form.

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.